Gene-activated matrices as nanomedicine platforms for bone regeneration: Delivery, translation and patent landscape
Materials Today Bio · 2026-12 · 41 · 103808
DOI: 10.1016/j.mtbio.2026.103808 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Materials Today Bio, 2026-12. Verfasst von Hiba Abdelnabi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy, College of Medicine and Health Sciences, United Arab Emirates University UAEU, P.O. Box 15551, Al Ain, United Arab Emirates. Die Arbeit nennt 193 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: United Arab Emirates University.
Abstract (Originalsprache)
Protein biologics are constrained in critical-size bone defects not by insufficient potency, but by rapid clearance and the inability to sustain therapeutic signaling at the repair site. Dose escalation does not overcome this pharmacokinetic limitation and instead increases the risk of ectopic bone formation, osteolysis, and soft tissue toxicity. Sustained, localized delivery, not higher dosing, is the unmet requirement. Gene-activated matrices (GAM) address this problem by integrating nucleic acid cargo and delivery vectors within an implantable scaffold, converting infiltrating host cells into local sources of regenerative signals. This review examines GAMs as nanomedicine platforms for bone regeneration, tracing their development from scaffold bioactivity and the limitation of protein biologics to nucleic acid-based delivery. We compare viral vectors, lipid nanoparticles, polymeric polyplexes, calcium phosphate nanoparticles, and scaffold-integrated systems across transduction efficiency, expression kinetics, immunogenicity, and bone-site retention. We then examine how scaffold composition, architecture, and fabrication govern vector retention, release, and substrate-mediated transfection. This review then evaluates nucleic acid cargo selection and coordinated osteogenic and angiogenic gene delivery, including pDNA, mRNA, siRNA, miRNA, and explores emerging multi-factor, stimuli-responsive, and CRISPR-based GAMs alongside their translational constraints. A distinct feature of this review is its claim-level patent analysis, which identifies substantial intellectual-property white space in GAM development. Despite strong preclinical evidence, no GAM platform has simultaneously achieved scalable manufacturing, regulatory readiness as a combination product, and validation in a human-scale bone defect model. Clinical translation will require coordinated optimization of vector-scaffold interactions, manufacturing scalability, safety, and clinically relevant validation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Anatomy, College of Medicine and Health Sciences, United Arab Emirates University UAEU, P.O. Box 15551, Al Ain, United Arab Emirates.
Förderung
- United Arab Emirates University
Zitieren
APA
Abdelnabi, H., Alkaabi, S. M., Alderei, K. S., Alaryani, A. S., & Mohsin, S. (2026). Gene-activated matrices as nanomedicine platforms for bone regeneration: Delivery, translation and patent landscape. Materials Today Bio, 41, 103808. https://doi.org/10.1016/j.mtbio.2026.103808
Vancouver
Abdelnabi H, Alkaabi SM, Alderei KS, Alaryani AS, Mohsin S. Gene-activated matrices as nanomedicine platforms for bone regeneration: Delivery, translation and patent landscape. Materials Today Bio. 2026;41:103808. doi:10.1016/j.mtbio.2026.103808
BibTeX
@article{Abdelnabi2026,
author = {Abdelnabi, Hiba and Alkaabi, Salem Mohammed and Alderei, Khaled Saeed and Alaryani, Ahmad Sultan and Mohsin, Sahar},
title = {Gene-activated matrices as nanomedicine platforms for bone regeneration: Delivery, translation and patent landscape},
journal = {Materials Today Bio},
year = {2026},
volume = {41},
pages = {103808},
doi = {10.1016/j.mtbio.2026.103808}
}
EUVIMED